Key Highlights:
- Strides Pharma Science has received the Establishment Inspection Report (EIR) from the USFDA for its flagship Bengaluru manufacturing facility, formally closing the cGMP inspection conducted from May 12 to May 20, 2026. The inspection had concluded with five observations cited in Form 483.
- Strides submitted a response to all five observations within the stipulated timeline and implemented corrective and preventive actions. Following its assessment of the company’s response and remediation measures, the USFDA classified the inspection outcome as Voluntary Action Indicated (VAI) and issued the EIR.
- The Bengaluru facility manufactures pharmaceutical dosage forms including tablets, capsules and oral liquids for regulated and other international markets, supporting both existing commercial products and future growth opportunities. The inspection closure strengthens Strides’ regulatory track record and supports continued supply to global markets.
Implications:
The USFDA’s EIR and VAI classification provide regulatory closure for Strides Pharma’s Bengaluru facility following the five observations issued during the May 2026 inspection, reducing immediate regulatory uncertainty around one of its flagship manufacturing sites. With the facility supplying tablets, capsules and oral liquids to regulated international markets, the outcome supports continuity of commercial operations and future product opportunities. The successful implementation of corrective and preventive actions also reinforces Strides’ ability to address regulatory observations and maintain compliance across its manufacturing network, which can help preserve customer confidence and support its position in global markets.
Source: Express Pharma
